Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Receivables: 2015-2024

Historic Receivables for Spyre Therapeutics (SYRE) over the last 2 years, with Dec 2024 value amounting to $5.9 million.

  • Spyre Therapeutics' Receivables was N/A to $5.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $39.2 million, marking a year-over-year change of. This contributed to the annual value of $5.9 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, Spyre Therapeutics' Receivables is $5.9 million, which was up 73.68% from $3.4 million recorded in FY2015.
  • Over the past 5 years, Spyre Therapeutics' Receivables peaked at $5.9 million during FY2024, and registered a low of $5.9 million during FY2024.
  • Its 1-year average for Receivables is $5.9 million, with a median of $5.9 million in 2024.